Early-life peripheral infections reprogram retinal microglia and aggravate neovascular age-related macular

Masayuki Hata1,2, Maki Hata1, Elisabeth Mma Andriessen3

  • 1Department of Ophthalmology.

Insights

Past infections can cause lasting immune changes in the eye, increasing the risk of age-related macular degeneration (AMD). This immune memory exacerbates pathological neovascularization (nvAMD) later in life.

Area of Science:

  • Immunology
  • Ophthalmology
  • Genetics

Background:

  • Age-related macular degeneration (AMD) is a leading cause of blindness in the elderly.
  • While genetic factors are known, environmental triggers are crucial for AMD development.
  • Past infections, like Chlamydia pneumoniae, may predispose individuals to pathological neovascularization in AMD (nvAMD).

Purpose of the Study:

  • To investigate how peripheral infections influence the development of nvAMD.
  • To understand the role of epigenetic reprogramming in retinal immune cells following inflammation.
  • To identify molecular mechanisms linking past infections to exacerbated nvAMD.

Main Methods:

  • Utilized a mouse model of nvAMD with prior C. pneumoniae infection and endotoxin exposure.
  • Employed genetic ablation of specific immune cell populations.
  • Conducted single-cell assay for transposase-accessible chromatin sequencing (scATAC-seq) on retinal mononuclear phagocytes (MNPs).

Main Results:

  • Peripheral infections induced epigenetic reprogramming and a persistent memory state in retinal CX3CR1+ MNPs.
  • This immune imprinting, even after inflammation subsided, exacerbated choroidal neovascularization in the nvAMD model.
  • Activating transcription factor 3 (ATF3) was identified as a key mediator, polarizing MNPs toward a proangiogenic phenotype.

Conclusions:

  • Past bacterial endotoxin-induced inflammation can reprogram central nervous system-resident MNPs.
  • This reprogramming leads to immunological memory that aggravates pathological angiogenesis in the aging retina.
  • Targeting ATF3 may offer therapeutic strategies for nvAMD.